Oppenheimer Holdings led the funding round. The Series C brings Perspectum’s total amount raised since inception to about $120 million.
“We are excited to have Oppenheimer and British Patient Capital join our mission to create safer and more accurate imaging technologies that will help clinicians shorten patients’ diagnostic and treatment journeys,” said Dr. Rajarshi Banerjee, CEO of Perspectum. “This new funding will help us to continue innovating new products that will make healthcare safer by providing non-invasive alternatives to biopsy, totally changing how and when we can see and treat many diseases.”
Perspectum develops medical imaging tools to improve the diagnosis of metabolic diseases and cancer. Its flagship dia…